Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.38 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.36 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015232 | 0.87 | CHRM4 (0.42) | CHRM4ADRB1NOS2WNT3APRKCA | |
| SCHEMBL7013205 | 0.84 | CHRM4 (0.40) | CHRM4ADRB1NOS2WNT3AUSP25 | |
| SCHEMBL7011556 | 0.83 | CHRM4 (0.40) | CHRM4ADRB1PRKCAPRKCQPRKCD | |
| SCHEMBL7015888 | 0.82 | CHRM4 (0.39) | RENCHRM4ADRB1NOS2WNT3A | |
| SCHEMBL7018539 | 0.76 | CHRM4 (0.40) | CHRM4WNT3A | |
| SCHEMBL7010873 | 0.74 | CHRM4 (0.38) | CHRM4WNT3AHRH4 | |
| SCHEMBL7018379 | 0.71 | WNT3A (0.37) | CHRM4WNT3A | |
| SCHEMBL7020197 | 0.70 | SIGMAR1 (0.42) | — | |
| SCHEMBL28805791 | 0.69 | CHRM4 (0.46) | CHRM4 | |
| SCHEMBL2917177 | 0.68 | REN (0.35) | RENADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | REN 53/4885CHRM4 3076/4885ADRB1 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.